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OBJECTIVES This study was designed to elucidate possible mechanisms for the prognostic value of
troponin T (tnT).
BACKGROUND The reasons for the adverse prognosis associated with elevation of troponins in unstable
coronary artery disease are poorly understood.
METHODS Patients enrolled in the Fast Revascularization during InStability in CAD (FRISC-II) trial
were included. Clinical characteristics, findings at echocardiography and coronary angiogra-
phy, and prognosis were evaluated in relation to different tnT levels.
RESULTS Absence of significant coronary stenosis was more frequent and three-vessel disease or left
main stem stenosis was less frequent in patients without, compared with, detectable tnT. The
occurrence of visible thrombus increased with rising levels of tnT. In the group with the
highest levels of tnT, occlusion of the left circumflex artery was more common than in the
three other tnT groups, as was a left ventricular ejection fraction below 0.45. The one-year
risk of death in the noninvasive arm of the study increased by increasing levels of tnT (1.6%
to 4.6%), whereas the risk of myocardial infarction showed an inverted U-shaped curve and
was lower in the lowest (5.5%) and highest (8.4%) tnT groups than in the two intermediate
groups (17.5% and 16.2%).
CONCLUSIONS Any detectable elevation of tnT raises the probability of significant coronary stenosis and
thrombus formation and is associated with an increased risk of reinfarction and death.
However, at a more pronounced elevation of troponin, a higher proportion of patients has
a persistent occlusion of the culprit vessel and reduced left ventricular function, associated
with a high mortality but a modest risk of reinfarction. (J Am Coll Cardiol 2001;38:979–86)
© 2001 by the American College of Cardiology
The value of troponin T (tnT) or I for risk stratification in
unstable coronary artery disease (CAD), that is, non–ST-
segment elevation myocardial infarction (MI) and unstable
angina, is well established (1–3). However, the reasons for
the adverse prognosis associated with elevations of troponin
are not fully understood. The troponins are sensitive and
specific markers for myocardial necrosis (4), which might
occur in unstable CAD as a result of persistent or transient
thrombotic vessel occlusion at the site of plaque rupture or
erosion (5). Furthermore, small areas of myocardial necrosis
See page 987
caused by microembolizations from the thrombus, occlud-
ing arterioles and capillaries downstream, might be an
alternative or contributory cause of minor elevations of
troponin in unstable CAD (6). Recently, it has been shown
(7,8) that patients with unstable CAD and elevated tnT or
I had more widespread CAD than those without elevated
tnT or I and more often had complex lesion characteristics
and visible thrombus in the culprit vessel (7,9,10). The aim
of the present study was to further elucidate the mechanisms
behind the prognostic value of tnT in a large cohort of
patients with unstable CAD.
METHODS
Patients and study design. The present study was a
substudy of the FRISC-II (Fast Revascularization during
InStability in CAD) trial (11,12). In brief, the FRISC-II
was a prospective, multicenter trial in which 2,457 patients
were randomized to a noninvasive or an invasive strategy.
Furthermore, within each arm patients were randomized to
90 days treatment with low molecular weight heparin,
dalteparin or placebo.
Inclusion criteria were symptoms of myocardial ischemia
associated with ST-depression, T-wave inversion or eleva-
tion of available cardiac markers. Major exclusion criteria
were raised risk of bleeding, angioplasty performed within
past six months, waiting list for coronary revascularization
procedure, previous open-heart surgery, other severe cardiac
disease, renal insufficiency (serum creatinine .150 mg/l) or
other severe illness.
Written consent was obtained from all patients and the
protocol was approved by all local ethics committees.
Randomized treatment. All patients were initially treated
with either subcutaneous dalteparin or by intravenous infu-
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sion of standard heparin. The patients were randomized
within 48 h after the start of open-label dalteparin or
standard heparin. From randomization all patients received
dalteparin subcutaneously (120 U/kg) twice daily until the
early invasive procedure and for at least five days in the
noninvasive arm. After this initial treatment, patients re-
ceived twice-daily subcutaneous injections of either dalte-
parin in a dose adjusted for weight and gender (5,000 to
7,500 U) or placebo for three months.
The early invasive strategy required coronary angiography
and, if appropriate, revascularization within seven days from
start of open-label dalteparin. The noninvasive strategy
included coronary angiography only in patients with refrac-
tory symptoms, severe ischemia at a predischarge symptom-
limited exercise test, or severe angina or MI during follow-
up.
The patient flow in the present substudy is outlined in
Figure 1.
Blood samples for biochemical markers. At randomiza-
tion ethylenediamine tetraacetate-plasma samples were ob-
tained from 2,329 patients (95%) and stored frozen at
270°C for central analysis of tnT with a third-generation
tnT assay on an Elecsys 2010 (13). The analytical range
extends from 0.01 to 25 mg/l and the upper reference level,
defined as the 99th percentile of healthy controls, is below
the lower limit of the analytical range. At our laboratory the
intra-assay CV was 7.9% (n 5 19) and interassay CV was
11.2% (n 5 8) at the low end of the analytical range (tnT 5
0.037 mg/l).
The patients were divided in four groups based on tnT
levels: the first group consisted of all patients without
measurable tnT (,0.01 mg/l, n 5 623) and the others of the
first, second and third tertile, respectively, of the remaining
patients (0.01 to 0.17 mg/l, n 5 570; 0.18 to 0.63 mg/l, n 5
569; and .0.63 mg/l, n 5 567).
ECG and echocardiogram. The admission (qualifying)
12-lead electrocardiograms (ECGs) were evaluated at a core
laboratory. Rhythm, presence and location of pathological
Q-waves, ST-segment depression ($0.05 mV) and T-wave
inversion were recorded.
Echocardiograms were obtained in 1,867 (80%) of the
patients before discharge and always before any invasive
procedure. All echocardiograms were evaluated centrally
and the left ventricular ejection fraction was visually as-
sessed. A depressed systolic left ventricular function was
considered present when the ejection fraction was below
0.45.
Coronary angiogram. In 1,142 (98.4%) of the 1,161 pa-
tients randomized to an invasive policy and with tnT
determined at randomization, a coronary angiogram was
performed at a median of four days (25th to 75th percentile;
3 to 5 days) from admission (Fig. 1). The coronary angio-
grams were evaluated locally according to a detailed protocol
and without knowledge of tnT status. The coronary vessels
were divided in 16 segments (14) and degree of stenosis,
Thrombolysis In Myocardial Infarction (TIMI) flow grade
and any visible thrombus were noted in each of these
segments. A $50% diameter obstruction in at least one of
Abbreviations and Acronyms
CAD 5 coronary artery disease
ECG 5 electrocardiogram
FRISC-II 5 Fast Revascularization during InStability
in CAD
MI 5 myocardial infarction
TIMI 5 Thrombolysis In Myocardial Infarction
tnT 5 troponin T
Figure 1. Patient flow in the present substudy.
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the segments in the respective vessel area (right coronary,
left anterior descending and left circumflex artery) was
considered significant in respect of the traditional one-,
two- or three-vessel disease. Also for the left main artery, a
$50% diameter stenosis was considered significant. The
evaluator of the coronary angiogram was urged to identify
and localize the culprit lesion to a single segment, which was
possible in 652 patients (56%).
Clinical end points. The relation between tnT levels and
clinical outcome at 12 months was evaluated in the nonin-
vasive arm of the study (Fig. 1). The noninvasive arm was
chosen because of the marked influence of an invasive
strategy on subsequent events (11,12). The randomization
to three months of dalteparin versus placebo was not
considered, as it did not influence the long-term outcome
(11). The clinical end points used in the present analysis
were total death, MI and revascularization (due to incapac-
itating or recurrent symptoms or severe ischemia at the
exercise test). Details about the follow-up and evaluation
procedures and definitions have been published elsewhere
(11,12).
Statistics. Differences in proportions were evaluated by
chi-square test. The Kruskal-Wallis one-way analysis of
variance was used to test the equality of distributions in the
four tnT groups.
Adjusted relative risk ratios and 95% confidence intervals
in relation to tnT levels were calculated for occurrence of
depressed left ventricular ejection fraction and findings at
coronary angiography, respectively, by multiple logistic re-
gression analysis. To identify independent predictors of
death and MI, respectively, multiple logistic regression
analyses were applied, forcing all the tested variables into
the models.
For all statistical analyses a significant difference was
considered to exist at the p , 0.05 levels. All calculations
were done with the SPSS system 10.0 (SPSS Inc., Chicago,
Illinois).
RESULTS
Clinical data, echocardiogram and tnT. The blood sam-
ple for analysis of tnT was obtained at randomization,
which took place in median 38.6 h (25th to 75th percentile,
26.8 to 54.0 h) from onset of last episode of chest pain.
Seventy-three percent, 58% and 47% of the patients had a
tnT level $0.01, $0.1 and $0.2 mg/l, respectively.
The clinical characteristics at inclusion according to tnT
levels are shown in Table 1. The patients with, compared to
without, detectable tnT were older and more often had
ST-segment depression and abnormal Q-waves on admis-
sion ECG. The proportion of men increased by increasing
levels of tnT. In contrast, the proportion of patients with a
history of stable angina, previous angioplasty and use of
aspirin, beta blockade and other cardiovascular drugs de-
Table 1. Baseline Characteristics According to Troponin T Levels (n 5 2,329)
Variable (%)
Troponin T
<0.01 0.01–0.17 0.18–0.63 >0.63 mg/l p Value
n 623 570 569 567
Age, gender, delay
Age (yrs)* 64.2 (56–70) 66.8 (59–73) 65.9 (59–72) 66.3 (58–72) , 0.001
Men 59.4 66.8 74.3 79.0 , 0.001
Delay (h)* 36.8 (26–53) 38.5 (26–54) 37.3 (27–54) 42.2 (28–56) 0.14
Coronary risk factors
Hypertension 30.0 33.0 31.3 27.9 0.37
Current smoker 28.7 28.2 29.0 33.2 0.24
Diabetes mellitus 11.7 11.8 14.2 11.6 0.47
Cholesterol .5.5 mmol/l 60.2 61.0 56.5 51.6 0.006
Previous and current cardiac disease
Previous MI 20.2 25.6 21.8 23.6 0.14
Previous PTCA 5.8 3.9 1.8 1.4 , 0.001
CHF 3.7 3.5 1.9 3.2 0.30
Angina .3 months 42.1 40.5 31.1 28.2 , 0.001
Chest pain at rest 77.2 82.2 81.9 82.5 0.06
Medication at admission prior to randomization
Aspirin 40.1 42.5 32.3 27.9 , 0.001
Beta blockade 40.8 34.6 29.2 24.9 , 0.001
Calcium antagonist 18.1 19.1 18.3 16.8 0.78
Long-acting nitrate 24.4 22.6 15.6 14.8 , 0.001
ACE-inhibitor 13.5 14.7 12.0 9.5 0.05
Diuretic 16.7 17.7 13.4 13.1 0.06
Admission ECG
ST-segment depression 39.0 48.3 47.0 51.0 , 0.001
Abnormal Q-wave 15.2 15.8 19.9 23.3 0.001
*Median and interquartile range.
ACE 5 angiotensin-converting enzyme; CHF 5 congestive heart failure (pharmacologically treated); Delay 5 delay from onset of symptoms to blood sampling; ECG 5
electrocardiogram; MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary angioplasty.
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creased with increasing levels of tnT. There was no signif-
icant association between tnT levels and traditional risk
factors (except for cholesterol level), previous MI, pharma-
cologically treated congestive heart failure or chest pain at
rest.
A left ventricular ejection fraction below 0.45 was signif-
icantly more common, also after adjusting for several pos-
sible confounders, in the group with the highest levels of
tnT (.0.63 mg/l) compared with every other tnT group
(Table 2A and B).
Coronary angiography and tnT in the invasive arm. The
proportion of patients without significant stenosis was
higher and the proportion of three-vessel disease or left
main stem stenosis was lower in patients without, compared
to with, detectable tnT. However, among patients with
detectable tnT there was no relation between severity of
CAD and the level of tnT. In contrast, the occurrence of
visible thrombus and TIMI flow 0 to 1 in at least one vessel
gradually increased by rising levels of tnT (Table 3A). The
same patterns were found irrespective of gender, although
the absolute numbers differed; that is, among men and
women with tnT ,0.01 mg/l, no significant stenosis could
be demonstrated in 26% and 43%, respectively, and among
those with tnT $0.01 mg/l in 4.4% and 14.3%, respectively.
The demonstrated associations between the tnT level and
the severity of CAD, occurrence of visible thrombus and
TIMI flow grade were consistent also after adjusting for
several possible confounders (Table 3B).
Among those with tnT ,0.01, 0.01 to 0.17, 0.18 to 0.63
and .0.63 mg/l, the proportions of patients with total or
subtotal occlusion (TIMI flow 0 or 1) of a culprit lesion in
the left circumflex artery territory, were 4%, 4%, 12% and
22% (p , 0.001), respectively. The corresponding figures
for the left anterior descending artery territory were 8%,
10%, 12% and 12% (p 5 0.62) and for the right coronary
artery territory 7%, 5%, 8% and 9% (p 5 0.48).
Prognosis and tnT. The frequency of death, MI, revascu-
larization and the combined end point death/MI at 12
Table 2. Findings at Echocardiography (n 5 1,867) in Relation to Troponin T Levels
A. Percentage of patients with depressed LVEF (,0.45)
Troponin T
<0.01 0.01–0.17 0.18–0.63 >0.63 mg/l p Value*
LVEF ,0.45 8.5 11.8 11.8 20.3† , 0.001
B. Adjusted‡ odds ratio (95% confidence interval) for occurrence of depressed LVEF (,0.45)
Troponin T
<0.01 0.01–0.17 0.18–0.63 >0.63 mg/l
LVEF ,0.45 1 1.08 (0.69–1.71) 1.12 (0.70–1.80) 2.29 (1.48–3.54)
*Global chi-square; †p # 0.001 group 4 compared with each of the other three groups; ‡Adjusted for gender, age, diabetes,
chronic angina, previous myocardial infarction, hypertension, any medication for angina on admission, any medication for
congestive heart failure at admission, ST-segment depression on admission and Q-wave on admission.
LVEF 5 left ventricular ejection fraction.
Table 3. Findings at Coronary Angiography in the Invasive Cohort (n 5 1,142) in Relation to Troponin T Levels
A. Percentage of patients with 0-vd, 3-vd/mss, visible thrombus, TIMI flow grade 0–1 in any vessel and TIMI flow grade 3 in all vessels
%
Troponin T
<0.01 0.01–0.17 0.18 6 0.63 >0.63 mg/l p Value
0-vd 32.4 8.7 9.3 2.6 , 0.001
3-vd/mss 22.8 38.8 34.9 35.9 , 0.001
Visible thrombus 2.9 8.0 11.7 15.7 , 0.001
TIMI 0–1 (n 5 1,137) 21.3 31.3 38.7 47.6 , 0.001
TIMI 3 (n 5 1,137) 66.8 52.7 49.5 39.6 , 0.001
B. Adjusted* odds ratio (95% confidence interval) for the different angiographic findings
Troponin T
<0.01 0.01–0.17 0.18–0.63 >0.63 mg/l
0-vd 1 0.20 (0.12–0.33) 0.21 (0.13–0.35) 0.06 (0.03–0.13)
3-vd/mss 1 1.84 (1.23–2.74) 1.75 (1.16–2.62) 1.97 (1.31–2.97)
Visible thrombus 1 2.90 (1.30–6.46) 4.23 (1.96–9.13) 5.70 (2.67–12.2)
TIMI 0–1 1 1.54 (1.02–2.30) 2.58 (1.73–3.83) 3.80 (2.54–5.67)
TIMI 3 1 0.59 (0.41–0.85) 0.46 (0.32–0.66) 0.30 (0.21–0.43)
*Adjusted for gender, age, ST-segment depression, diabetes, chronic angina, previous myocardial infarction, hypertension, chest pain at rest, current smoking, aspirin treatment
on admission and time from start of open label dalteparin to angiography.
0-vd 5 no significant stenosis; 3-vd/mss 5 3-vessel disease of left main stem stenosis; TIMI 5 Thrombolysis In Myocardial Infarction.
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months in relation to the different tnT levels in the
noninvasive group are shown in Table 4. The risk of death
showed a trend to a gradual increase by increasing levels of
tnT. However, the risk of MI, revascularization and the
composite of death and MI were lowest in the lowest,
modest in the highest and highest in the two intermediate
tnT groups (Fig. 2).
The prognostic value of tnT regarding death and MI,
respectively, was evaluated in models using multivariate
logistic regression analysis (Table 5). After adjustment for
age, gender, diabetes, hypertension, a history of stable
angina or previous MI and ST-segment depression, patients
with a tnT $0.17 mg/l had an approximately tripled risk of
death compared with patients without any myocardial
damage, and there was a trend to increased risk also among
those with only a minor myocardial damage (tnT 0.01 to
0.17 mg/l). Somewhat differently, the relative risk of MI was
also significantly and substantially elevated in patients with
tnT 0.01 to 0.17 mg/l as tnT 0.18 to 0.63 mg/l. However,
the risk of MI in patients with the largest myocardial
damage (tnT .0.63 mg/l) was not significantly higher than
in patients without detectable myocardial damage.
The influence of the left ventricular ejection fraction on
the predictive values of any tnT elevation (tnT $0.01 mg/l)
was studied in the subgroup of 961 patients with an
echocardiogram obtained. The relative risk ratio for death at
12 months decreased from 2.01 to 1.73 after adjustment for
the left ventricular ejection fraction ($/,0.45), whereas the
relative risk ratio for MI was virtually unchanged after
adjustment (from 2.52 to 2.45).
DISCUSSION
The unique design of the present study gave specific
advantages in attempts to further elucidate the possible
mechanisms for the prognostic value of troponin concerning
mortality and myocardial (re-)infarctions in unstable CAD.
The relation between tnT and baseline characteristics, ECG
findings and left ventricular ejection fraction could be
reliably evaluated in the large cohort of the whole trial. The
relation between the tnT level and the coronary lesions and
blood flow could be evaluated in the half of the population
randomized to an early coronary angiogram. Finally, the
prognostic information in tnT and other factors could be
evaluated without the influence of early revascularization
procedures in the other half of the population randomized
to the noninvasive arm of the study, which mainly reflected
the “natural course” of the coronary lesions and their
consequences in unstable CAD.
Prognosis and tnT. The mortality among patients without
elevation of tnT was low, in accordance with previous
studies (2,3). The one-year mortality of 1.6% in patients
without any measurable tnT elevation was close to the
Figure 2. Death and myocardial infarction (MI) rate at 12 months, respectively, in relation to troponin T (tnT) levels.
Table 4. Clinical End Points at 12 Months in the Noninvasive Cohort in Relation to Troponin
T Levels (n 5 1,168)
Troponin T
<0.01 0.01–0.17 0.18–0.63 >0.63 mg/l p Value
Death 1.6 3.8 4.6 4.5 0.17
MI 5.5 17.5 16.2 8.4 , 0.001
Death/MI 6.8 20.3 17.6 11.5 , 0.001
Revascularization 38.8 51.9 46.1 34.3 , 0.001
MI 5 myocardial infarction.
983JACC Vol. 38, No. 4, 2001 Lindahl et al.
October 2001:979–86 Mechanisms Behind the Prognostic Value of Troponin T
annual mortality of 1.7% found in patients with stable
angina pectoris (15). However, at any sign of myocardial
damage there was a strong trend to an increased mortality in
accordance with previous findings (2). The relation between
the tnT level and the risk of subsequent MI showed a
somewhat different pattern. The one-year risk of MI was
lowest in the group without detectable tnT, 5.5%, which is
approximately twice as high as the annual rate of MI found
in patients with stable angina pectoris (15). In the two
intermediate tnT groups the rate of MI during follow-up
was substantially higher, 16.2% to 17.5%, indicating a
severely unstable coronary lesion as the underlying condi-
tion. However, rather unexpectedly, the rate of re-MI in
those with the highest levels of tnT was only 8.4%, which
was only marginally higher than in those without any tnT
elevation. The one-year rate of reinfarction in this group
resembles the one-year reinfarction rate of 6.4% after a
Q-wave infarction in the Framingham heart study (16).
Thus, the risk of myocardial (re-)infarction in relation to
tnT level showed an inverted U-shaped curve in the present
study (Fig. 2), that has not previously been described.
However, in retrospect, the same association between tnT
level and risk of MI could be seen in the FRISC-1 trial (2).
The proportion of patients requiring a revascularization
procedure during follow-up in the four tnT groups showed
a similar inverted U-shaped curve. This finding supports the
concept of a more unstable coronary lesion in the two
intermediate groups than in the lowest and highest tnT
groups.
Clinical characteristics, tnT and risk of future events.
Several baseline variables known to be associated with an
increased risk of new coronary events differed in relation to
tnT levels. Patients without elevation of tnT were somewhat
younger, more often women and less likely to have ST-
segment depression at the admission ECG. However, there
was no consistent pattern that indicated that patients with
elevated tnT constituted a more sick population; on the
contrary, several factors known to be associated with an
increased risk of adverse events, such as previous angina,
antianginal medication and higher cholesterol levels, were
more common in patients without elevation of tnT, in
accordance with some (10), but not all, previous studies
(17). Thus, it is unlikely that the relation between the tnT
levels and baseline characteristics is a major determinant of
the prognostic value of tnT, especially as tnT remained an
independent prognostic factor in multivariate analysis.
Coronary angiogram, tnT and risk of future events. The
extent of CAD is a major determinant of the prognosis in
unstable CAD, with a very low risk of cardiac events in
patients without significant obstructions (18) and the high-
est risk in those with three-vessel or left main disease (19).
Furthermore, complex lesions, occurrence of visible throm-
bus and decreased TIMI flow grade have been associated
with the risk of death and MI (20). Only a few studies have
evaluated findings at coronary angiography in relation to
troponin levels in patients with unstable CAD (7–10). In
the present study, the largest so far, there were significant
relations between the tnT level and the extent and type of
coronary lesions and coronary blood flow. In this large
cohort it was possible to demonstrate that these relations
remained after adjustment for differences in baseline vari-
ables, excluding the possibility that these relations were
merely a reflection of such differences. Despite a clinical
diagnosis of unstable CAD in all patients, 26% of the men
and 43% of the women without any measurable elevation of
tnT (,0.01 mg/l) did not have significant coronary stenosis.
In contrast, in men and women with tnT elevation and thus
myocardial damage, 4% and 14%, respectively, had no
significant obstruction, which is close to the figures in
patients with non–ST-elevation MI in the GUSTO IIb
study, 4.2% and 9.1%, respectively (21). The gender differ-
ence might be explained by differences in thrombotic
activity as well as in the underlying substrate of coronary
thrombosis between the sexes (22,23). Patients with any
sign of myocardial damage more often had three-vessel
disease or left main stem stenosis (35% to 40%) than did
those without detectable tnT (23%). These findings are in
accordance with previous smaller studies showing more
frequent triple-vessel and left main coronary artery involve-
ment in patients with elevated troponin (7,8). Thus, the
relation between the tnT levels and the extent of CAD
Table 5. Multivariate Logistic Regression Analyses Regarding Death and MI at 12 Months,




p ValueOR 95% CI OR 95% CI
TnT ,0.01 1 1
0.01–0.17 2.27 0.69–7.42 0.18 3.01 1.66–5.45 , 0.001
0.18–0.63 3.09 0.97–9.83 0.06 2.82 1.54–5.16 0.001
$0.64 mg/l 2.88 0.88–9.34 0.08 1.28 0.66–2.50 0.47
Age (per 10 years) 1.66 1.06–2.60 0.03 1.55 1.21–1.97 , 0.001
ST-segment depression 1.81 0.90–3.65 0.10 1.56 1.06–2.29 0.03
Female gender 0.72 0.34–1.55 0.40 0.60 0.39–0.93 0.02
Diabetes 4.52 2.25–9.10 , 0.001 2.11 1.30–3.42 0.002
Previous MI or angina 1.74 0.85–3.55 0.13 1.94 1.31–2.89 0.001
Hypertension 1.33 0.68–2.62 0.41 1.11 0.75–1.66 0.59
CI 5 confidence interval; MI 5 myocardial infarction; OR 5 odds ratio; TnT 5 troponin T.
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might explain some of the prognostic value of elevated tnT
levels.
Coronary thrombus, tnT and risk of future events. By
increasing levels of tnT there was a graded rise, from 3% to
16%, in occurrence of visible intracoronary thrombus, in
accordance with the study of Heeschen et al. (10). The
incidences of visible intracoronary thrombi in patients with
tnT ,0.01 mg/l were very low (,3%) in our study as well as
in their study (10), and comparable to patients with stable
angina pectoris (2%) (24). However, it should be empha-
sized that visual evaluation of coronary angiograms from
patients with unstable CAD is associated with a substantial
underestimate of the occurrence of intracoronary thrombi in
comparison to intracoronary angioscopy (25). Therefore,
the occurrence of intracoronary thrombi at increasing tnT
levels probably is considerably larger than apparent in the
current study. Thus, the relation between tnT and remain-
ing thrombi at the coronary lesions might be one explana-
tion for the relation between tnT level and risk of early
(re-)infarction.
Coronary occlusion, tnT and risk of future events. In the
present study there was also a relation between the tnT level
and impairment of coronary blood flow, in accordance with
Heeschen et al. (10). This was due mainly to a rise in
occurrence of total or subtotal occlusions by increasing levels
of tnT. The high incidence of total or subtotal occlusions,
especially of the circumflex artery or its branches, in the
group with the highest tnT levels suggests that many of the
patients in this group might have had a “transmural”
infarction that was undetected by the standard 12-lead
ECG on admission (26). The higher rate of completed
infarctions at the highest tnT levels might explain the lower
risk of reinfarction and lower need for revascularization, in
analogy with the lower risk of reinfarction in patients after
a Q-wave compared with a non–Q-wave infarction (17).
Left ventricular ejection fraction, tnT and risk of future
events. The left ventricular function has a major impact on
mortality (27). The tnT level has been shown to correlate
with infarct size (28) and left ventricular ejection fraction
(29). A depressed left ventricular ejection fraction at the
echocardiogram was significantly more common in the
group with the highest tnT levels (.0.63 mg/l) in the
present study (Table 2A). This relation also remained after
adjustment for baseline variables possibly associated with a
depressed left ventricular function (Table 2B), indicating
that the lower ejection fraction in the group with the highest
tnT levels was indeed a result of the myocardial damage
associated with the index event. Thus, the increased mor-
tality found at a tnT level .0.63 mg/l might be a conse-
quence of myocardial damage large enough to cause a
decreased left ventricular function. However, left ventricular
dysfunction was no explanation for the increased risk of
death in patients with only minor elevations of tnT. Thus,
the association between a minor tnT elevation and future
mortality probably is related to the raised risk of reinfarc-
tion.
Study limitations. One limitation of the present study is
that tnT was determined only at randomization, at a median
of 38.6 h from onset of last episode of chest pain. However,
because tnT levels remain elevated for 10 to 14 days in
patients with myocardial necrosis (30), very few false neg-
ative results should have occurred. It is also important to
recognize that tnT was determined with the new third-
generation assay, which has slightly different properties,
such as a lower upper reference level, compared with the
second-generation assay.
Another limitation of the study is that the coronary
angiograms were not assessed centrally. However, the eval-
uation was performed according to a predefined protocol.
The striking similarities regarding the occurrence of coro-
nary thrombus and TIMI flow grade in the present study, as
in the previous study by Heeschen et al. (10) with central
evaluation, corroborate our results.
Conclusions and clinical implications. These results, to-
gether with previous experiences, suggest that much of the
prognostic value of troponins in unstable CAD can be
attributed to underlying severe coronary stenosis, culprit
lesion thrombosis, downstream embolization with microin-
farction and, in some patients, total coronary occlusion and
a large MI. The group without any tnT elevation consists
partly of patients without significant atherosclerotic CAD,
whose symptoms often have noncardiac causes, and partly of
patients with CAD, whose symptoms might be caused by an
increase of oxygen demand or a decrease in oxygen supply
unrelated to coronary thrombosis. At any detectable eleva-
tion of tnT the probability of significant coronary stenosis is
considerably raised, and there is an increased likelihood of
an unstable plaque with thrombus and downstream micro-
embolization and impairment of coronary flow, all factors
associated with a raised risk of reinfarction and death.
However, with a more pronounced elevation of troponin, a
higher proportion of patients will have a persistent occlusion
of the culprit coronary vessel associated with reduced left
ventricular function, resembling a Q-wave infarction with a
high mortality but lower risk of reinfarction.
These results also give a reasonable explanation of why
treatment with coagulation or platelet inhibition, which
reduces the risk of thromboembolic events, is protective
mainly in patients with elevated troponin (31–33).
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